Research Papers

Receptor-targeted quantum dots: fluorescent probes for brain tumor diagnosis

[+] Author Affiliations
Jingjing Wang

University of Southern California, Department of Biomedical Engineering, Los Angeles, California 90089

William H. Yong

University of California, Los Angeles, Department of Pathology and Laboratory Medicine, Los Angeles, California 90048

Yinghua Sun

University of California, Davis, Department of Biomedical Engineering, Los Angeles, California 90007

P. Thomas Vernier

University of Southern California, MOSIS, Information Sciences Institute, Marina del Rey, California 90292

H. Phillip Koeffler

Cedars-Sinai Medical Center, Division of Hematology and Oncology, Los Angeles, California 90048

Martin A. Gundersen

University of Southern California, Department of Electrical Engineering-Electrophysics, Los Angeles, California 90089

Laura Marcu

University of California, Davis, Department of Biomedical Engineering, Genome and Biomedical Sciences Bulding, 451 East Health Sciences Drive, Davis, California 95616

J. Biomed. Opt. 12(4), 044021 (July 30, 2007). doi:10.1117/1.2764463
History: Received November 08, 2006; Revised March 11, 2007; Accepted March 16, 2007; Published July 30, 2007
Text Size: A A A

The intraoperative diagnosis of brain tumors and the timely evaluation of biomarkers that can guide therapy are hindered by the paucity of rapid adjunctive studies. This study evaluates the feasibility and specificity of using quantum dot-labeled antibodies for rapid visualization of epidermal growth factor receptor (EGFR) expression in human brain tumor cells and in surgical frozen section slides of glioma tissue. Streptavidin-coated quantum dots (QDs) were conjugated to anti-EGFR antibodies and incubated with target cultured tumor cells and tissues. The experiments were conducted first in human glioma tumor cell lines with elevated levels of EGFR expression (SKMG-3, U87) and then in frozen tissue sections of glioblastoma multiforme and of oligodendroglioma. The bioconjugated QDs used in the study were found to bind selectively to brain tumor cells expressing EGFR. QD complexed quickly to the cell membrane (less than 15min), and binding was highly specific and depended on the expression level of EGFR on the cell membrane. Tissue experiments showed that only tumor specimens expressing EGFR were labeled in less than 30min by QD complexes. These findings demonstrate that QD-labeled antibodies can provide a quick and accurate method for characterizing the presence or absence of a specific predictive biomarker.

Figures in this Article
© 2007 Society of Photo-Optical Instrumentation Engineers

Citation

Jingjing Wang ; William H. Yong ; Yinghua Sun ; P. Thomas Vernier ; H. Phillip Koeffler, et al.
"Receptor-targeted quantum dots: fluorescent probes for brain tumor diagnosis", J. Biomed. Opt. 12(4), 044021 (July 30, 2007). ; http://dx.doi.org/10.1117/1.2764463


Tables

Access This Article
Sign in or Create a personal account to Buy this article ($20 for members, $25 for non-members).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Related Book Chapters

Topic Collections

PubMed Articles
Advertisement
  • Don't have an account?
  • Subscribe to the SPIE Digital Library
  • Create a FREE account to sign up for Digital Library content alerts and gain access to institutional subscriptions remotely.
Access This Article
Sign in or Create a personal account to Buy this article ($20 for members, $25 for non-members).
Access This Proceeding
Sign in or Create a personal account to Buy this article ($15 for members, $18 for non-members).
Access This Chapter

Access to SPIE eBooks is limited to subscribing institutions and is not available as part of a personal subscription. Print or electronic versions of individual SPIE books may be purchased via SPIE.org.